N/A N=4 Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract
High Risk Polyposis Syndrome · Distal Colonic Lesions · Colorectal Polyps
Primary: Number of Neoplastic Lesions Detected — 3 Lesions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders
Autism Spectrum Disorder
Primary: Preschool Language Scales — 7.6 Raw score units / 16 weeks
N/A N=155 Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Participant Assessment of Present Pain Intensity Recorded on a Visual Analogue Scale (VAS) at Baseline and Months 3, 6, 9, and 12 — 58.32; 34.28; 27.14; 21.71 units on a…
N/A N=203 The Impact of Vitamin D on Tuberculosis Among Koreans
Tuberculosis
Primary: Prevalence of Vitamin D Deficiency — 36.2; 27.3 participants, %
N/A N=73 Culturally-Tailored Approach to Improve Medication Use in Patients With Heart Attacks
Coronary Arteriosclerosis · Myocardial Infarction
Primary: Achievement of LDL-cholesterol Goals — 31; 29 participants
Phase 3 N=869 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169 — 0.186; 0.208; 0.223; 0.149 Liters — p=0.377
N/A N=71 Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis
Peripheral Vascular Diseases
Primary: Successful Completion of the Assigned Treatment — 76.7 percentage of subjects
Phase 4 N=478 Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to 24 Weeks Endpoint (Per Protocol Population) — -1.30; -1.09 percentage of HbA1c
Phase 2 N=7 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children
Dengue Fever
Primary: Number of Solicited Adverse Events Within 21 Days After the First Dose of Dengue Vaccine. — 1; 3; 5; 3 adverse events
Phase 2 N=285 28-day Repeat Dose Study of GSK573719
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Day 29 — 0.013; 0.171; 0.181; 0.163 Liters — p=<0.001
Phase 2 N=100 Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
Influenza
Primary: Haemagglutination Inhibition (HI) Antibody Titers for the H5N1 Vaccine Strain — 5.0; 5.4; 156.8; 142.1 Titer
Phase 2 N=4 Development of an Ergonomic Wheelchair Pushrim
Spinal Cord Injury
Primary: Change in Functional Status Score
N/A N=30 Improving Vitamin D Status In Cystic Fibrosis
Cystic Fibrosis
Primary: 25-hydroxyvitamin D — 21.2; 24.4; 28.2 ng/mL
N/A N=47 Treatment of the Face and Neck With Lower Ulthera System Energy Settings
Skin Laxity
Primary: Subjects' Assessment of Pain During Treatment With Lower Energy Settings — 4.5; 6.0; 5.6; 3.7 units on a scale
N/A N=500 Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab
Psoriasis
Primary: Mean Change of Dermatology Life Quality Index (DLQI) Scores — 4.9; 9.3; 11.3; 12.1 units on a scale